Severe pneumococcal pneumonia: Impact of new quinolones on prognosis

BMC Infectious Diseases

Volumn 11, Issue , 2011, Pages

  Olive, David ^a   Georges, Hugues ^a   Devos, Patrick ^b   Boussekey, Nicolas ^a   Chiche, Arnaud ^a   Meybeck, Agnes ^a   Alfandari, Serge ^a   Leroy, Olivier ^a  

^a Hôpital Chatiliez   (France)

^b LILLE UNIVERSITY HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN PLUS CLAVULANIC ACID; CEPHALOSPORIN; CIPROFLOXACIN; LEVOFLOXACIN; OFLOXACIN; PIPERACILLIN PLUS TAZOBACTAM; ANTIINFECTIVE AGENT; BETA LACTAM; QUINOLONE DERIVATIVE;

ADULT; AGING; ARTICLE; COMMUNITY ACQUIRED PNEUMONIA; CONTROLLED STUDY; FEMALE; HUMAN; INTENSIVE CARE UNIT; MAJOR CLINICAL STUDY; MALE; MORTALITY; OUTCOME ASSESSMENT; PROGNOSIS; RETROSPECTIVE STUDY; RISK FACTOR; SEPTIC SHOCK; SURVIVAL RATE; TREATMENT OUTCOME; AGED; DRUG EFFECT; MIDDLE AGED; PATHOLOGY; STREPTOCOCCUS PNEUMONIA; STREPTOCOCCUS PNEUMONIAE;

AGED; AGED, 80 AND OVER; ANTI-BACTERIAL AGENTS; BETA-LACTAMS; FEMALE; HUMANS; MALE; MIDDLE AGED; PNEUMONIA, PNEUMOCOCCAL; PROGNOSIS; QUINOLONES; RETROSPECTIVE STUDIES; STREPTOCOCCUS PNEUMONIAE; TREATMENT OUTCOME;

EID: 79952567634     PISSN: None     EISSN: 14712334     Source Type: Journal    
DOI: 10.1186/1471-2334-11-66     Document Type: Article

References (32)

1. Georges H, Leroy O, Vandenbussche C, Guery B, Alfandari S, Tronchon L, Beaucaire G. Epidemiological features and prognosis of severe community-acquired pneumococcal pneumonia. Intensive Care Med 1999, 25:198-206. 10.1007/s001340050816, 10193548.
2. Quatrième conférence de consensus en thérapeutique anti-infectieuse de la société de pathologie infectieuse de langue française Les infections des voies respiratoires. Med Mal Inf 1991, 21(suppl Oct):1-8. Quatrième conférence de consensus en thérapeutique anti-infectieuse de la société de pathologie infectieuse de langue française.
3. Huchon G, Chidiac C, Delaval P, Léophonte P, Mouton Y, Roche N, Trémolières F. Management of community-acquired lower respiratory tract infection in the adult. Recommendations by the French Language Society of Pneumology with collaboration of the French Language Society of Infectious Pathology, from the recommendations of the European Respiratory Society. Rev Mal Respir 1999, 16:224-233.
4. Bartlett JG, Dowell SF, Mandell LA, File TM, Musher DM, Fine MJ. Practice guidelines for the management of community-acquired pneumonia in adults. Infectious Diseases Society of America. Clin Infect Dis 2000, 31:347-382. 10.1086/313954, 10987697.
5. Niederman MS, Mandell LA, Anzueto A, Bass JB, Broughton WA, Campbell GD, Dean N, File T, Fine MJ, Gross PA, Martinez F, Marrie TJ, Plouffe JF, Ramirez J, Sarosi GA, Torres A, Wilson R, Yu VL, . American Thoracic Society Guidelines for the management of adults with community-acquired pneumonia. Diagnosis, assessment of severity, antimicrobial therapy, and prevention. Am J Respir Crit Care Med 2001, 163:1730-1754. American Thoracic Society.
6. Woodhead M, Blasi F, Ewig S, Huchon G, Ieven M, Ortqvist A, Schaberg T, Torres A, van der Heijden G, Verheij TJ, . European Respiratory Society; European Society of Clinical Microbiology and Infectious Diseases Guidelines for the management of adult lower respiratory tract infections. Eur Respir J 2005, 26:1138-1180. 10.1183/09031936.05.00055705, 16319346, European Respiratory Society; European Society of Clinical Microbiology and Infectious Diseases.
7. XVe conférence de consensus en thérapeutique anti-infectieuse Prise en charge des infections des voies respiratoires basses de l'adulte immunocompétent. Med Mal Inf 2006, 36:235-244. XVe conférence de consensus en thérapeutique anti-infectieuse.
8. Mandell LA, Wunderink RG, Anzueto A, Bartlett JG, Campbell GD, Dean NC, Dowell SF, File TM, Musher DM, Niederman MS, Torres A, Whitney CG. Infectious Diseases Society of America; American Thoracic Society: Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. Clin Infect Dis 2007, 44(Suppl 2):S27-72. 10.1086/511159, 17278083.
9. Rodríguez A, Mendia A, Sirvent JM, Barcenilla F, de la Torre-Prados MV, Solé-Violán J, Rello J, . CAPUCI Study Group Combination antibiotic therapy improves survival in patients with community-acquired pneumonia and shock. Crit Care Med 2007, 35:1493-1498. CAPUCI Study Group.
10. Fine MJ, Auble TE, Yealy DM, Hanusa BH, Weissfeld LA, Singer DE, Coley CM, Marrie TJ, Kapoor WN. A prediction rule to identify low-risk patients with communityacquired pneumonia. N Engl J Med 1997, 336:243-250. 10.1056/NEJM199701233360402, 8995086.
11. Levy MM, Fink MP, Marshall JC, Abraham E, Angus D, Cook D, Cohen J, Opal SM, Vincent JL, Ramsay G, . International Sepsis Definitions Conference 2001 SCCM/ESICM/ACCP/ATS/SIS International Sepsis Definitions Conference. Intensive Care Med 2003, 29:530-538. International Sepsis Definitions Conference.
12. Le Gall JR, Lemeshow S, Saulnier F. A new Simplified Acute Physiology Score (SAPS II) based on a European/North American multicenter study. JAMA 1993, 270:2957-2963. 10.1001/jama.270.24.2957, 8254858.
13. Vincent JL, Moreno R, Takala J, Willatts S, De Mendonça A, Bruining H, Reinhart CK, Suter PM, Thijs LG. The SOFA (Sepsis-related Organ Failure Assessment) score to describe organ dysfunction/failure: on behalf of the Working Group on Sepsis-Related Problems of the European Society of Intensive Care Medicine. Intensive Care Med 1996, 22:707-710. 10.1007/BF01709751, 8844239.
14. Le Gall JR, Klar J, Lemeshow S, Saulnier F, Alberti C, Artigas A, Teres D. The Logistic Organ Dysfunction system: a new way to assess organ dysfunction in the intensive care unit; ICU Scoring Group. JAMA 1996, 276:802-810. 10.1001/jama.276.10.802, 8769590.
15. Tran DD, Groeneveld AB, van der Meulen J, Nauta JJ, Strack van Schijndel RJ, Thijs LG. Age, chronic disease, sepsis, organ system failure, and mortality in a medical intensive care unit. Crit Care Med 1990, 18:474-479. 10.1097/00003246-199005000-00002, 2328591.
16. Bernard GR, Artigas A, Brigham KL, Carlet J, Falke K, Hudson L, Lamy M, Legall JR, Morris A, Spragg R. The American-European consensus conference on ARDS. Am J Respir Crit Care Med 1994, 149:818-824.
17. Garner JS, Jarvis WR, Emori TG, Horan TC, Hughes JM. CDC definitions for nosocomial infections. Am J Infect Control 1988, 16:128-140. 10.1016/0196-6553(88)90053-3, 2841893.
18. Davis R, Bryson HM. Levofloxacin. A review of its antibacterial activity, pharmacokinetics and therapeutic efficacy. Drugs 1994, 47:677-700. 10.2165/00003495-199447040-00008, 7516863.
19. Thomson KS, Chartrand SA, Sanders CC, Block SL. In-vitro activity of levofloxacin against Streptococcus pneumoniae with various levels of penicillin resistance. J Antimicrob Chemother 1999, 43(Suppl C):15-19. 10.1093/jac/43.suppl_3.15, 10404332.
20. File TM, Segreti J, Dunbar L, Player R, Kohler R, Williams RR, Kojak C, Rubin A. A multicenter, randomized study comparing the efficacy and safety of intravenous and/or oral levofloxacin versus ceftriaxone and/or cefuroxime axetil in treatment of adults with community-acquired pneumonia. Antimicrob Agents Chemother 1997, 41:1965-1972. 164046, 9303395.
21. Frank E, Liu J, Kinasewitz G, Moran GJ, Oross MP, Olson WH, Reichl V, Freitag S, Bahal N, Wiesinger BA, Tennenberg A, Kahn JB. A multicenter, open-label, randomized comparison of levofloxacin vs azithromycin plus ceftriaxone in hospitalized adults with moderate to severe community-acquired pneumonia. Clin Therap 2002, 8:1292-1308.
22. Fogarty C, Siami G, Kohler R, File TM, Tennenberg AM, Olson WH, Wiesinger BA, Scott Marshall JA, Oross M, Kahn JB. Multicenter, open-label, randomized study to compare the safety and efficacy of levofloxacin versus ceftriaxone sodium and erythromycin followed by clarithromycin and amoxicillin-clavulanate in the treatment of serious community-acquired pneumonia in adults. Clin Infect Dis 2004, 38:S16-23.
23. Leroy O, Saux P, Bédos JP, Caulin E, . for the levofloxacin study group Comparison of levofloxacin and cefotaxime combined with ofloxacin for ICU patients with community-acquired pneumonia who do not require vasopressors. Chest 2005, 128:172-183. 10.1378/chest.128.1.172, 16002932, for the levofloxacin study group.
24. Kühn F, Cottagnoud M, Acosta F, Flatz L, Entenza J, Cottagnoud P. Cefotaxime acts synergistically with levofloxacin in experimental meningitis due to penicillin resistant pneumococci and prevents selection of levofloxacin-resistant mutants in vitro. Antimicrob Agents Chemother 2003, 47:2487-2491. 166100, 12878509.
25. Gimeno C, Borja J, Navarro D, Valdés L, García-Barbal J, García-de-Lomas J. In vitro interaction between ofloxacin and cefotaxime against gram-positive and gram negative bacteria involved in serious infections. Chemotherapy 1998, 44:94-98. 10.1159/000007098, 9551238.
26. Waterer GW, Somes GW, Wunderink RG. Monotherapy may be suboptimal for severe bacteremic pneumococcal pneumonia. Arch Intern Med 2001, 161:1837-1842. 10.1001/archinte.161.15.1837, 11493124.
27. Baddour LM, Yu VL, Klugman KP, Feldman C, Ortqvist A, Rello J, Morris AJ, Luna CM, Snydman DR, Ko WC, Chedid MB, Hui DS, Andremont A, Chiou CC. International Pneumococcal Study Group: Combination antibiotic therapy lowers mortality among severely ill patients with pneumococcal bacteremia. Am J Respir Crit Care Med 2004, 170:440-444. 10.1164/rccm.200311-1578OC, 15184200.
28. The Acute Respiratory Distress Syndrome Network Ventilation with lower tidal volumes as compared with traditional tidal volumes for Acute Lung Injury and the Acute Respiratory Distress Syndrome. N Engl J Med 2000, 342:1301-1308. 10.1056/NEJM200005043421801, 10793162, The Acute Respiratory Distress Syndrome Network.
29. Dellinger RP, Levy MM, Carlet JM, Bion J, Parker MM, Jaeschke R, Reinhart K, Angus DC, Brun-Buisson C, Beale R, Calandra T, Dhainaut JF, Gerlach H, Harvey M, Marini JJ, Marshall J, Ranieri M, Ramsay G, Sevransky J, Thompson BT, Townsend S, Vender JS, Zimmerman JL, Vincent JL. Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock. Intensive Care Med 2008, 34:17-60. 10.1007/s00134-007-0934-2, 2249616, 18058085.
30. Siempos II, Vardakas KZ, Kopterides P, Falagas ME. Adjunctive therapies for community-acquired pneumonia: a systematic review. J Antimicrob Chemother 2008, 62:661-668. 10.1093/jac/dkn283, 18641037.
31. Finfer S, Chittock DR, Su SY, Blair D, Foster D, Dhingra V, Bellomo R, Cook D, Dodek P, Henderson WR, Hébert PC, Heritier S, Heyland DK, McArthur C, McDonald E, Mitchell I, Myburgh JA, Norton R, Potter J, Robinson BG, Ronco JJ. NICE-SUGAR Study Investigators Intensive versus conventional glucose control in critically ill patients. N Engl J Med 2009, 360:1283-1287. 10.1056/NEJMoa0810625, 19318384, NICE-SUGAR Study Investigators.
32. Ferrer R, Artigas A, Suarez D, Palencia E, Levy MM, Arenzana A, Pérez XL, Sirvent JM, . Edusepsis Study Group Effectiveness of treatments for severe sepsis. Am J Respir Crit Care Med 2009, 180:861-866. 10.1164/rccm.200812-1912OC, 19696442, Edusepsis Study Group.